financetom
Business
financetom
/
Business
/
Update: NeuroPace Prices $65 Million Public Offering; Shares Jump
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: NeuroPace Prices $65 Million Public Offering; Shares Jump
Feb 14, 2025 11:37 AM

02:09 PM EST, 02/14/2025 (MT Newswires) -- (Updates with the stock movement in the headline and the last paragraph.)

NeuroPace ( NPCE ) said Friday it has priced a public offering of 6.5 million shares at $10 per share.

Gross proceeds from the offering, expected to close on Feb. 18, are expected to be $65 million, the company said.

NeuroPace ( NPCE ) said it has also granted underwriters a 30-day option to purchase up to 975,000 additional shares.

The company said it expects to use around $49.5 million of net proceeds from the offering to acquire 5.3 million shares held by KCK at $9.40 per share, and the remainder for general corporate purposes.

Shares of the company were up more than 8% in recent Friday trading.

Price: 13.09, Change: +1.00, Percent Change: +8.27

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ocugen Receives European Medicines Agency Committee's Acceptance for OCU410ST Study
Ocugen Receives European Medicines Agency Committee's Acceptance for OCU410ST Study
Aug 13, 2025
08:17 AM EDT, 08/13/2025 (MT Newswires) -- Ocugen ( OCGN ) said Wednesday that the European Medicines Agency's Committee for Medicinal Products for Human Use provided acceptability for a phase 2/3 trial of OCU410ST to submit for a marketing authorization application. The company said the acceptance is based on results from its phase 1 GARDian trial. It added that the...
Texas Sues Eli Lilly For Alleged Kickback Scheme Involving Mounjaro, Zepbound
Texas Sues Eli Lilly For Alleged Kickback Scheme Involving Mounjaro, Zepbound
Aug 13, 2025
Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. ( LLY ) , accusing the pharmaceutical giant of bribing medical providers to promote its most profitable drugs, including the widely used GLP-1 medications Mounjaro and Zepbound for diabetes and weight loss. Paxton alleges the company’s conduct violated state fraud prevention laws and defrauded taxpayers through...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Gildan Activewear Buying HanesBrands for US$2.2 Billion in Cash and Shares
Gildan Activewear Buying HanesBrands for US$2.2 Billion in Cash and Shares
Aug 13, 2025
07:58 AM EDT, 08/13/2025 (MT Newswires) -- Gildan Activewear ( GIL ) is slightly lower in U.S. pre-market trade after announcing its acquisition of HanesBrands in a US$2.2 billion cash and share deal. HanesBrands shareholders will receive 0.102 share of Gildan and US$0.80 cash per share. The offer implies a value of US$6 per Hanesbrands share, based on Gildan's closing...
Copyright 2023-2026 - www.financetom.com All Rights Reserved